A patent-focused intellectual property boutique, with an emphasis on biotech and pharmaceuticals, Groombridge Wu Baughman & Stone got off to a roaring start in 2023 as entity calving off from Paul Weiss with a trial-centric approach and a wave of peer review fueling its market momentum. “This is an IP shop to watch,” advises one peer. “They broke off and took all of their clients with them, and they are steadfastly loyal because [Groombridge Wu] can try cases.” Another elaborates, “They get hired for cases of some enterprise significance. They skew largely in favor of life sciences. There’s a great balance there of
Nicholas Groombridge, the polished, eloquent, seasoned statesman, and the group of other name partners (Eric Stone,
Steven Baughman and Jennifer Wu, who are younger and really roll up their sleeves and get involved in the trenches.” The firm maintains an almost even 50/50 balance of plaintiff and defendant work. Groombridge and Stone represent Acuitas, who invented the essential lipid nanoparticle that is used in the COVID-19 vaccine from BioNTech and Pfizer and who has been sued by a number of other entities attempting to claim credit in the wake of the enormous success of the mRNA vaccines during the pandemic. Groombridge, Wu and Baughman are lead counsel for plaintiffs 10x and Stanford University in litigation in the District of Delaware asserting six patents on key technology relating to single-cell sequencing.
